Impact of reimbursement policies on prudent use, availabillity and - PowerPoint PPT Presentation

Impact of reimbursement policies on prudent use, availabillity and pipeline of new antibacterials Ad Schuurman London, 8th November

Quick review Short interviews 26 EU countries • Competent Authorities • Departments of Health • Reimbursement organisations (assessment and payers) • Actual, but not scientific • 2

Results 20 have no reimbursement policies • 4 (?) trust on doctors guidelines (some monitor doctor prescribing) • 20 follow normal reimbursement procedures for AMB’s • 2 special committee has to approve reimbursement AMB (high • price) 1 uses co payment • 1 essential list AMB • 10 committee rational use (information, monitoring, • recommendation treatment 2(?) promote innovation/ investment • 2 campagne to population • 3

General aspects In patient: hospital policy (not transparent) • Out patient: committees • Veterinary system can be dangerous • 4